Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Oct 29;6(6):pkac075. doi: 10.1093/jncics/pkac075

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2022. Published by Oxford University Press.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Figure 3. — Proportion of patients in the POLAR studies with moderate-to-severe chemotherapy-induced peripheral neuropathy by treatment and visit (combined mITT set). These patients had a score of 3 or 4 on at least 1 of the first 4 items of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity 13-item subscale at each treatment visit (cycle) and at 9 months (primary endpoint). C = cycle; CaM = calmangafodipir; mITT = modified intention-to-treat; POLAR = Preventive Treatment of OxaLiplatin Induced peripherAl neuRopathy.